🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Namrata Sethi

Yale University

ORCID: 0000-0003-1586-3338

Also affiliated with University of New Haven

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma”.

Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0057

N/A

0.292DataRank · unranked

6 citations

Cem Demirkiran, Stefania Bellone, Tobias M.P. Hartwich, Blair McNamara, Victoria M. Ettorre +7 more

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.06.017

N/A

0DataRank · unranked

3 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Victoria M. Ettorre, Blair McNamara +7 more

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor

International Journal of Molecular Sciences(2025)10.3390/ijms26188924

N/A

0DataRank · unranked

2 citations

Stefania Bellone, Victoria M. Ettorre, Miranda Mansolf, Tobias M.P. Hartwich, Blair McNamara +11 more

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

(2025)10.22541/au.174523361.14689067/v1

N/A

0DataRank · unranked

1 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Victoria M. Ettorre, Blair McNamara +7 more